Read by QxMD icon Read

Journal of Viral Hepatitis

Richard Njouom, Isabelle Siffert, Gaëtan Texier, Guillaume Lachenal, Mathurin Cyrille Tejiokem, Jacques Pépin, Arnaud Fontanet
Cameroon is thought to have one of the highest prevalences of Hepatitis C virus (HCV) infection in the world (4·9% among adults). A marked cohort effect exists in several communities where ≈50% of the elderly are infected. Better assessment of HCV distribution is needed for planning treatment programs. We tested for HCV antibodies 14150 capillary blood samples collected during the 2011 Demographic and Health Survey, whose participants were representative of the Cameroonian population aged 15-49 (both genders) and 50-59 years (men only)...
March 13, 2018: Journal of Viral Hepatitis
Nicolas Goossens, Claudio de Vito, Alessandra Mangia, Sophie Clément, Giovanni Cenderello, Francisco Barrera, Roberta D'Ambrosio, Nicola Coppola, Rosa Zampino, Maria Stanzione, Luigi Elio Adinolfi, Heiner Wedemeyer, Nasser Semmo, Beat Müllhaupt, David Semela, Raffaele Malinverni, Darius Moradpour, Markus Heim, Gaia Trincucci, Laura Rubbia-Brandt, Francesco Negro
It remains unclear whether hepatitis B virus (HBV) infection may modify the severity of viral steatosis in patients coinfected with chronic hepatitis C virus (HCV). We examined the influence of coinfection with HBV on prevalence of steatosis in chronic hepatitis C in a multi-center cohort of HBV-HCV subjects, and by performing a systematic review and meta-analysis of the literature. We centrally and blindly assessed steatosis prevalence and severity in a cohort of HBV-HCV coinfected subjects compared to HCV and HBV monoinfected controls and we performed a systematic review of studies addressing the prevalence of steatosis in HBV-HCV subjects compared to HCV controls...
March 13, 2018: Journal of Viral Hepatitis
Youkyung H Choi, Xiugen Zhang, Coleen Tran, Brianna Skinner
Hepatitis E virus (HEV) genotype (gt) 3 infection is food-borne causing sporadic infections in older individuals and gt1 infection is water-borne, often causing epidemics affecting primarily young adults. Although HEV infection causes self-limited disease, gt3 induces chronic infection in immunocompromised individuals. Hepatic host gene expression against gt3 infection remains unknown. Host gene expression profiles for HEV gt1 (n=3) and gt3 (n=7) infections were analyzed in the livers of experimentally infected rhesus macaques...
March 13, 2018: Journal of Viral Hepatitis
Mengge Li, Yu Gan, Chunsun Fan, Hui Yuan, Xianjing Zhang, Yuling Shen, Qing Wang, Zihong Meng, Dengfei Xu, Hong Tu
Previous studies have focused on the relationship between hepatitis B virus (HBV) infection and non-Hodgkin lymphoma (NHL). However, the results remain inconsistent and somehow conflicting in different sub-groups. The aim of this study was to combine the findings of independent studies to comprehensively assess the association between HBV and NHL using a meta-analysis. Relevant studies were identified through structured keyword searches in PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) database and 58 studies with a total of 53,714 NHL cases and 1,778,591 controls were finally included...
March 13, 2018: Journal of Viral Hepatitis
Bo Wang, Ivana Carey, Matthew Bruce, Sarah Montague, Geoff Dusheiko, Kosh Agarwal
HBeAg seroconversion marks an important spontaneous change and treatment end-point for HBeAg-positive patients and is a pre-requisite for HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg-positive patients treated with nucleos(t)ide analogues (NA). Data and samples from 118 HBeAg-positive adults (genotypes A-G) started on NA between Jan 2005-Sept 2016 were retrospectively analysed at several time-points...
March 13, 2018: Journal of Viral Hepatitis
Ugo Fedeli
According to data available for selected countries on the burden of Hepatitis C virus (HCV) infection, ongoing transmission through intravenous drug use is displayed by a higher prevalence in young males, while historical transmission through unsafe traditional and medical practices is reflected by an older infected population [1]. While the overall prevalence of HCV infection is decreasing in most countries, morbidity and mortality attributable to HCV are expected to increase as the current infected population progresses to the advanced stages of liver disease [2]...
March 13, 2018: Journal of Viral Hepatitis
Guilherme Duarte, Christopher J Williams, Paula Vasconcelos, Paulo Nogueira
Viral hepatitis is globally leading causes of death and 96% of these are due to Hepatitis B and C (HBV/HCV) late outcomes. The first Global Health Sector Strategy (GHSS) aims to reduce by 65% the mortality associated with HBV/HCV and an indicator (C10) is proposed to monitor progress. Data on viral hepatitis and liver-related mortality is required and different methods of estimation can be used, depending on availability and quality of sources. We aimed to understand the current situation and practicality of calculating C10, accessing available sources in order to estimate initial figure for Europe...
February 25, 2018: Journal of Viral Hepatitis
Charles D MacLean, Claudia Berger, Michelle L Cangiano, David Ziegelman, Steven D Lidofsky
Screening for Hepatitis C virus (HCV) was recommended in 2012 by the Centers for Disease Control (CDC) for the population born between 1946-1965. Reminder systems are effective at promoting HCV screening, but the yield of positive tests among various population subgroups and the linkage to specialty HCV treatment is not well understood. We sought to determine: 1) the effect of the CDC recommendation alone, and the effect of an EMR reminder on the proportion of the population screened; 2) the yield of positive HCV tests as screening strategies have evolved, and according to a patient's history of serum aminotransferase testing; 3) the proportion of positive cases followed-up for HCV treatment...
February 25, 2018: Journal of Viral Hepatitis
Jennifer Y Chen, Yanjie Ren, Peng Yan, Morgan E Belina, Raymond T Chung, Adeel A Butt
Recent preclinical studies have suggested an antifibrotic role for tricyclic antidepressants. Using the Electronically Retrieved Cohort of HCV Infected Veterans, we aimed to evaluate the impact of TCA use on fibrosis progression and development of hepatocellular carcinoma (HCC) among HCV-infected persons. Subjects were categorized according to use of tricyclic antidepressants, selective serotonin reuptake inhibitors, or no antidepressants. tricyclic antidepressants or selective serotonin uptake inhibitors use was defined according to cumulative defined daily dose, and categories were mutually exclusive...
February 25, 2018: Journal of Viral Hepatitis
Jia Li, Talan Zhang, Stuart C Gordon, Loralee B Rupp, Sheri Trudeau, Scott D Holmberg, Anne C Moorman, Philip R Spradling, Eyasu H Teshale, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Mei Lu
Data regarding the impact of hepatitis C (HCV) therapy on incidence of type 2 diabetes mellitus are limited. We used data from the longitudinal Chronic Hepatitis Cohort Study-drawn from four large US health systems-to investigate how response to HCV treatment impacts risk of subsequent type 2 diabetes mellitus. Among HCV patients without a history of type 2 diabetes mellitus or hepatitis B, we investigated incidence of type 2 diabetes mellitus from 12 weeks post-HCV treatment through December 2015. Cox proportional hazards models were used to test the effect of treatment status (sustained virological response [SVR] or treatment failure) and baseline risk factors on development of type 2 diabetes mellitus, considering any possible risk factor-by-SVR interactions and death as a competing risk...
February 25, 2018: Journal of Viral Hepatitis
Zobair M Younossi, Atsushi Tanaka, Yuichiro Eguchi, Linda Henry, Rachel Beckerman, Masashi Mizokami
Hepatocellular carcinoma (HCC) is a serious complication of hepatitis B and (HBV) C virus (HCV) infection. Sustained virologic response (SVR) for HCV is associated with a reduction in cirrhosis, HCC and mortality and their associated costs. Japanese HCV patients are older with higher prevalence of HCC. Here we used a decision analytic Markov model to estimate the economic benefit of HCV cure by reducing HCC and DCC in Japan. A cohort of 10,000 HCV genotype 1b (GT1b) Japanese patients was modeled with a hybrid decision tree and Markov state-transition model capturing natural history of HCV over a lifetime horizon...
February 25, 2018: Journal of Viral Hepatitis
Antonio Olveira, Lourdes Domínguez, Jesús Troya, Ana Arias, Federico Pulido, Pablo Ryan, Laura María Benítez, Juan González-García, María Luisa Montes
Guidelines recommend evaluating persistent alteration of liver tests in HCV-infected patients after sustained virological response (SVR) and its influence on liver disease progression. We studied the prevalence, aetiology, associated factors, and evolutionary implications of persistent alteration of liver tests in HCV patients after direct-acting antivirals (DAA) -induced SVR. This was a prospective study of HCV-infected patients and SVR after DAA. Those with another previously diagnosed liver disease were excluded...
February 24, 2018: Journal of Viral Hepatitis
P Cacoub, P Buggisch, J A Carrión, G S Cooke, A L Zignego, R Beckerman, Z Younossi
Hepatitis C virus (HCV) infection is a systemic disease associated with both hepatic and extrahepatic manifestations. The burden associated with the hepatic manifestation of HCV infection has been well-documented in Europe, although that of HCV extrahepatic manifestations remains unknown. In this study, we estimated the annual direct medical costs associated with HCV extrahepatic manifestations in five European countries. A previously validated economic model was used to estimate the annual direct medical cost associated with HCV extrahepatic manifestations...
February 24, 2018: Journal of Viral Hepatitis
Wei-Chen Lee, Hong-Shiue Chou, Ching-Song Lee, Tsung-Han Wu, Yu-Chao Wang, Chih-Hsien Cheng, Chen-Fang Lee, Ting-Jung Wu, Kun-Ming Chan
Indications of liver transplantation are extensive, but deceased donation does not meet the demand. Hepatitis B surface antigen (HBs Ag)-positive grafts used to be discarded in the past. The aim of this study is to examine viral activity and outcome of HBsAg-positive deceased grafts transplanted to HBsAg-positive recipients. Eleven HBsAg-positive deceased grafts were transplanted to HBsAg-positive patients with acute liver failure (3 patients), hepatocellular carcinoma (6 patients) and repeatedly bleeding varices (2 patients)...
February 12, 2018: Journal of Viral Hepatitis
Paolo A Cortesi, Luca S Belli, Rita Facchetti, Chiara Mazzarelli, Giovanni Perricone, Stella De Nicola, Giancarlo Cesana, Christophe Duvoux, Lorenzo G Mantovani, Mario Strazzabosco
Different strategies of DAAs treatment are currently possible both pre and post liver-transplantation (LT). Clinical and economic consequences of these strategies still need to be adequately investigated; this study aims at assessing their cost-effectiveness. A decision-analytical model was created to simulate the progression of HCV-infected patients listed for decompensated cirrhosis (DCC) or for Hepatocellular carcinoma (HCC). Three DAAs treatment strategies were compared: (i) a 12-week course of DAAs prior to transplantation (PRE-LT), (ii) a 4-week course of DAAs starting at the time of transplantation (PERI-LT), and (iii) a 12-week course of DAAs administered at disease recurrence (POST-LT)...
February 6, 2018: Journal of Viral Hepatitis
Magnus Hedenstierna, Ali Nangarhari, Amin El-Sabini, Ola Weiland, Soo Aleman
We aimed to assess fibrosis with liver stiffness measurement long-term after sustained virologic response of chronic hepatitis C, and to identify risk factors associated with persisting fibrosis. In this cross-sectional study, patients with chronic hepatitis C and pre-treatment advanced fibrosis or cirrhosis treated successfully at Karolinska University Hospital with an interferon-containing regimen, underwent liver stiffness measurement with FibroScan. The impact of potential risk factors for persisting fibrosis was estimated...
February 6, 2018: Journal of Viral Hepatitis
Cecilia María Delfino, Carolina Susana Cerrudo, Mirna Biglione, José Raúl Oubiña, Pablo Daniel Ghiringhelli, Verónica Lidia Mathet
In association with hepatitis B virus (HBV), hepatitis delta virus (HDV) is a subviral agent that may promote severe acute and chronic forms of liver disease. Based on the percentage of nucleotide identity of the genome, HDV was initially classified into three genotypes. However, since 2006, the original classification has been further expanded into eight clades/genotypes. The intergenotype divergence may be as high as 35-40% over the entire RNA genome, whereas sequence heterogeneity among the isolates of a given genotype is <20%; furthermore, HDV recombinants have been clearly demonstrated...
February 6, 2018: Journal of Viral Hepatitis
G C Zhong, Y L Wu, F B Hao, X W Rao, X W Yuan, Y Zhao, J P Gong
The relation between hepatitis B virus (HBV) infection and fatty liver has been addressed by several observational studies, but their results remain controversial. To date, no study has precisely investigated the association of current and past HBV infection with the risk of nonalcoholic fatty liver disease (NAFLD) in the Chinese population. Therefore, we conducted a hospital-based case-control study in southwestern China to clarify this issue. A total of 631 newly ultrasound-diagnosed NAFLD cases and 2357 controls were selected from 123243 consecutive patients admitted to a tertiary-care hospital between January 2015 and December 2016...
February 6, 2018: Journal of Viral Hepatitis
Haidy Mohammed Zakaria, Tahany Abdel-Hamid Salem, Hanaa Ahmed El-Araby, Rawan Mohammed Salama, Doaa Yousry Elbadry, Ahmad Mohamed Sira, Mohammed Abdul-Hafeez Ali, Menan El-Sayed Salem, Basma Mahmoud Abd-Alaaty, Shaimaa Samy Goda, Sara Mohammed Eltaras, Fatma Omar Khalil, Sahar Shahein Abou-Zeinah, Mostafa Mohamed Sira
Fulminant hepatic failure is a life-threatening disease. Hepatitis A virus (HAV) can cause fulminant hepatic failure and death in about 0.2% of cases. Extensive destruction of infected hepatocytes by immune-mediated lysis is thought to be the cause. We aimed to evaluate the use of steroid therapy in children with fulminant HAV. This study included 33 children with fulminant HAV in two groups. Steroid group; comprised of 18 children who received prednisolone (1 mg/kg/d) or its equivalent dose of methylprednisolone and the non-steroid group; comprised another 15 children who did not receive steroid therapy...
February 3, 2018: Journal of Viral Hepatitis
C M Preda, C P Popescu, C Baicus, I Constantinescu, A Oproiu, T Voiosu, M Diculescu, L Negreanu, L Gheorghe, I Sporea, A Trifan, E Ceausu, D Proca, M Manuc
Hepatitis B virus may reactivate in patients with chronic hepatitis C treated with direct-acting antivirals. The aim of this study was to investigate the risk of hepatitis B virus (HBV) reactivation in HBV + hepatitis C virus (HCV)-co-infected patients with compensated liver cirrhosis treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin. We reviewed prospectively gathered data from a national cohort of 2070 hepatitis C virus patients with compensated liver cirrhosis who received reimbursed paritaprevir/ombitasvir/r, dasabuvir with ribavirin for 12 weeks from the Romanian National Health Agency during 2015-2016...
February 3, 2018: Journal of Viral Hepatitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"